O	O	O	0	10	Monoclonal	Monoclonal	B-NP	JJ	B-protein	6	NMOD	B-protein
O	O	O	11	15	anti	anti	I-NP	AFX	I-protein	6	NMOD	I-protein
O	O	O	15	16	-	-	I-NP	HYPH	O	6	P	O
O	O	O	16	27	endothelial	endothelial	I-NP	JJ	B-protein	6	NMOD	B-protein
O	O	O	28	32	cell	cell	I-NP	NN	I-protein	6	NMOD	I-protein
O	O	O	33	43	antibodies	antibody	I-NP	NNS	I-protein	13	SUB	I-protein
O	O	O	44	48	from	from	B-PP	IN	O	6	NMOD	O
O	O	O	49	50	a	a	B-NP	DT	O	9	NMOD	O
O	O	O	51	58	patient	patient	I-NP	NN	O	7	PMOD	O
O	O	O	59	63	with	with	B-PP	IN	O	9	NMOD	O
O	O	O	64	72	Takayasu	Takayasu	B-NP	NN	O	12	NMOD	O
O	O	O	73	82	arteritis	arteritis	I-NP	NN	O	10	PMOD	O
O	O	O	83	91	activate	activate	B-VP	VBP	O	0	ROOT	O
O	O	O	92	103	endothelial	endothelial	B-NP	JJ	B-cell_type	15	NMOD	B-cell_type
O	O	O	104	109	cells	cell	I-NP	NNS	I-cell_type	13	OBJ	I-cell_type
O	O	O	110	114	from	from	B-PP	IN	O	13	VMOD	O
O	O	O	115	120	large	large	B-NP	JJ	O	18	NMOD	O
O	O	O	121	128	vessels	vessel	I-NP	NNS	O	16	PMOD	O
O	O	O	128	129	.	.	O	.	O	13	P	O

O	O	O	131	140	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT	O
O	O	O	140	141	:	:	O	:	O	1	P	O
O	O	O	142	144	To	To	B-VP	TO	O	4	VMOD	O
O	O	O	145	151	create	create	I-VP	VB	O	1	NMOD	O
O	O	O	152	162	monoclonal	monoclonal	B-NP	JJ	B-protein	10	NMOD	B-protein
O	O	O	163	167	anti	anti	I-NP	AFX	I-protein	10	NMOD	I-protein
O	O	O	167	168	-	-	I-NP	HYPH	I-protein	10	NMOD	I-protein
O	O	O	168	179	endothelial	endothelial	I-NP	JJ	I-protein	10	NMOD	I-protein
O	O	O	180	184	cell	cell	I-NP	NN	I-protein	10	NMOD	I-protein
O	O	O	185	195	antibodies	antibody	I-NP	NNS	I-protein	4	OBJ	I-protein
O	O	O	196	197	(	(	O	(	O	13	DEP	O
O	O	O	197	202	mAECA	mAECA	B-NP	NNS	B-protein	13	DEP	B-protein
O	O	O	202	203	)	)	O	)	O	10	NMOD	O
O	O	O	204	208	from	from	B-PP	IN	O	10	NMOD	O
O	O	O	209	210	a	a	B-NP	DT	O	16	NMOD	O
O	O	O	211	218	patient	patient	I-NP	NN	O	14	PMOD	O
O	O	O	219	223	with	with	B-PP	IN	O	16	NMOD	O
O	O	O	224	232	Takayasu	Takayasu	B-NP	NN	O	19	NMOD	O
O	O	O	233	242	arteritis	arteritis	I-NP	NN	O	17	PMOD	O
O	O	O	243	245	to	to	B-VP	TO	O	21	VMOD	O
O	O	O	246	254	evaluate	evaluate	I-VP	VB	O	4	VMOD	O
O	O	O	255	260	their	their	B-NP	PRP$	O	23	NMOD	O
O	O	O	261	268	ability	ability	I-NP	NN	O	21	OBJ	O
O	O	O	269	271	to	to	B-VP	TO	O	25	VMOD	O
O	O	O	272	280	activate	activate	I-VP	VB	O	23	NMOD	O
O	O	O	281	286	human	human	B-NP	JJ	B-cell_type	30	NMOD	B-cell_type
O	O	O	287	296	umbilical	umbilical	I-NP	JJ	I-cell_type	30	NMOD	I-cell_type
O	O	O	297	301	vein	vein	I-NP	NN	I-cell_type	30	NMOD	I-cell_type
O	O	O	302	313	endothelial	endothelial	I-NP	JJ	I-cell_type	30	NMOD	I-cell_type
O	O	O	314	319	cells	cell	I-NP	NNS	I-cell_type	25	OBJ	I-cell_type
O	O	O	320	321	(	(	O	(	O	33	DEP	O
O	O	O	321	326	HUVEC	HUVEC	B-NP	NNS	B-cell_line	33	DEP	B-cell_line
O	O	O	326	327	)	)	O	)	O	30	NMOD	O
O	O	O	327	328	,	,	O	,	O	4	P	O
O	O	O	329	332	and	and	O	CC	O	4	VMOD	O
O	O	O	333	335	to	to	B-VP	TO	O	37	VMOD	O
O	O	O	336	348	characterize	characterize	I-VP	VB	O	4	VMOD	O
O	O	O	349	352	the	the	B-NP	DT	O	39	NMOD	O
O	O	O	353	362	mechanism	mechanism	I-NP	NN	O	37	OBJ	O
O	O	O	363	365	of	of	B-PP	IN	O	39	NMOD	O
O	O	O	366	368	EC	EC	B-NP	NN	B-cell_type	42	NMOD	B-cell_type
O	O	O	369	379	activation	activation	I-NP	NN	O	40	PMOD	O
O	O	O	379	380	.	.	O	.	O	1	P	O

O	O	O	381	388	METHODS	METHODS	B-NP	NNS	O	0	ROOT	O
O	O	O	388	389	:	:	O	:	O	1	P	O
O	O	O	390	391	A	A	B-NP	DT	O	4	NMOD	O
O	O	O	392	397	panel	panel	I-NP	NN	O	7	SUB	O
O	O	O	398	400	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	401	406	mAECA	mAECA	B-NP	NNS	B-protein	5	PMOD	B-protein
O	O	O	407	410	was	be	B-VP	VBD	O	1	NMOD	O
O	O	O	411	420	generated	generate	I-VP	VBN	O	7	VC	O
O	O	O	421	425	from	from	B-PP	IN	O	8	VMOD	O
O	O	O	426	436	peripheral	peripheral	B-NP	JJ	B-cell_type	12	NMOD	B-cell_type
O	O	O	437	442	blood	blood	I-NP	NN	I-cell_type	12	NMOD	I-cell_type
O	O	O	443	454	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	9	PMOD	I-cell_type
O	O	O	455	457	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	458	459	a	a	B-NP	DT	O	15	NMOD	O
O	O	O	460	467	patient	patient	I-NP	NN	O	13	PMOD	O
O	O	O	468	472	with	with	B-PP	IN	O	15	NMOD	O
O	O	O	473	481	Takayasu	Takayasu	B-NP	NN	O	18	NMOD	O
O	O	O	482	491	arteritis	arteritis	I-NP	NN	O	16	PMOD	O
O	O	O	491	492	,	,	O	,	O	8	P	O
O	O	O	493	498	using	use	B-VP	VBG	O	8	VMOD	O
O	O	O	499	506	Epstein	Epstein	B-NP	NNP	O	25	NMOD	O
O	O	O	506	507	-	-	I-NP	HYPH	O	23	P	O
O	O	O	507	511	Barr	Barr	I-NP	NNP	O	25	NMOD	O
O	O	O	512	517	virus	virus	I-NP	NN	O	25	NMOD	O
O	O	O	518	532	transformation	transformation	I-NP	NN	O	20	OBJ	O
O	O	O	532	533	.	.	O	.	O	1	P	O

O	O	O	534	542	Activity	Activity	B-NP	NN	O	21	SUB	O
O	O	O	543	550	against	against	B-PP	IN	O	1	NMOD	O
O	O	O	551	564	macrovascular	macrovascular	B-NP	JJ	B-cell_line	4	NMOD	B-cell_line
O	O	O	565	567	EC	EC	I-NP	NN	I-cell_line	10	NMOD	I-cell_line
O	O	O	568	569	(	(	O	(	O	7	DEP	O
O	O	O	569	574	HUVEC	HUVEC	B-NP	NN	B-cell_line	7	DEP	B-cell_line
O	O	O	574	575	)	)	O	)	O	4	NMOD	O
O	O	O	576	579	and	and	O	CC	O	10	NMOD	O
T12	B-Entity	B-Entity	580	593	microvascular	microvascular	B-NP	JJ	B-cell_line	10	NMOD	B-cell_line
T12	I-Entity	I-Entity	594	596	EC	EC	I-NP	NN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	597	598	(	(	O	(	O	20	NMOD	O
T12	I-Entity	I-Entity	598	603	human	human	B-NP	JJ	B-cell_line	20	NMOD	B-cell_line
T12	I-Entity	I-Entity	604	608	bone	bone	I-NP	NN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	609	615	marrow	marrow	I-NP	NN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	616	618	EC	EC	I-NP	NN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	619	631	immortalized	immortalize	B-VP	VBN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	632	634	by	by	B-PP	IN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	635	639	SV40	SV40	B-NP	NN	I-cell_line	20	NMOD	I-cell_line
T12	I-Entity	I-Entity	639	640	)	)	O	)	O	20	NMOD	O
T12	I-Entity	I-Entity	641	649	antigens	antigen	B-NP	NNS	O	2	PMOD	O
O	O	O	650	653	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	654	662	detected	detect	I-VP	VBN	O	21	VC	O
O	O	O	663	665	by	by	B-PP	IN	O	22	VMOD	O
O	O	O	666	672	enzyme	enzyme	B-NP	NN	B-protein	28	NMOD	B-protein
O	O	O	672	673	-	-	O	HYPH	O	28	NMOD	O
O	O	O	673	679	linked	link	B-VP	VBN	O	28	NMOD	O
O	O	O	680	693	immunosorbent	immunosorbent	B-NP	JJ	O	28	NMOD	O
O	O	O	694	699	assay	assay	I-NP	NN	O	23	PMOD	O
O	O	O	699	700	.	.	O	.	O	21	P	O

O	O	O	701	711	Inhibition	Inhibition	B-NP	NN	O	2	NMOD	O
O	O	O	712	719	studies	study	I-NP	NNS	O	3	SUB	O
O	O	O	720	724	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	725	729	used	use	I-VP	VBN	O	3	VC	O
O	O	O	730	732	to	to	B-VP	TO	O	6	VMOD	O
O	O	O	733	739	select	select	I-VP	VB	O	4	VMOD	O
O	O	O	740	743	the	the	B-NP	DT	O	9	NMOD	O
O	O	O	744	754	monoclonal	monoclonal	I-NP	JJ	B-protein	9	NMOD	B-protein
O	O	O	755	765	antibodies	antibody	I-NP	NNS	I-protein	6	OBJ	I-protein
O	O	O	766	767	(	(	O	(	O	12	DEP	O
O	O	O	767	772	mAECA	mAECA	B-NP	NNS	B-protein	12	DEP	B-protein
O	O	O	772	773	)	)	O	)	O	9	NMOD	O
O	O	O	774	779	which	which	B-NP	WDT	O	9	NMOD	O
O	O	O	780	785	share	share	B-VP	VBP	O	13	SBAR	O
O	O	O	786	789	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	790	794	same	same	I-NP	JJ	O	20	NMOD	O
T13	B-Entity	B-Entity	795	797	EC	EC	I-NP	NN	O	20	NMOD	O
T13	I-Entity	I-Entity	798	805	epitope	epitope	I-NP	NN	O	20	NMOD	O
O	O	O	806	813	binding	binding	I-NP	NN	O	20	NMOD	O
O	O	O	814	825	specificity	specificity	I-NP	NN	O	14	OBJ	O
O	O	O	826	828	as	as	B-PP	IN	O	14	VMOD	O
O	O	O	829	832	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	833	838	total	total	I-NP	JJ	O	26	NMOD	O
T1	B-Protein	B-Protein	839	842	IgG	IgG	I-NP	NN	B-protein	26	NMOD	B-protein
O	O	O	842	843	-	-	B-NP	HYPH	O	26	NMOD	O
O	O	O	843	847	AECA	AECA	I-NP	NN	B-protein	21	PMOD	B-protein
O	O	O	848	852	from	from	B-PP	IN	O	26	NMOD	O
O	O	O	853	856	the	the	B-NP	DT	O	31	NMOD	O
O	O	O	857	865	Takayasu	Takayasu	I-NP	NN	O	31	NMOD	O
O	O	O	866	875	arteritis	arteritis	I-NP	NN	O	31	NMOD	O
O	O	O	876	883	patient	patient	I-NP	NN	O	27	PMOD	O
O	O	O	883	884	.	.	O	.	O	3	P	O

O	O	O	885	888	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	889	896	binding	binding	I-NP	NN	O	10	SUB	O
O	O	O	897	899	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	900	903	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	904	909	mAECA	mAECA	I-NP	NNS	B-protein	3	PMOD	B-protein
O	O	O	910	912	to	to	B-PP	TO	O	2	NMOD	O
O	O	O	913	918	human	human	B-NP	JJ	B-cell_type	9	NMOD	B-cell_type
O	O	O	919	925	aortic	aortic	I-NP	JJ	I-cell_type	9	NMOD	I-cell_type
O	O	O	926	928	EC	EC	I-NP	NN	I-cell_type	6	PMOD	I-cell_type
O	O	O	929	932	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	933	940	studied	study	I-VP	VBN	O	10	VC	O
O	O	O	941	943	by	by	B-PP	IN	O	11	VMOD	O
O	O	O	944	964	immunohistochemistry	immunohistochemistry	B-NP	NN	O	12	PMOD	O
O	O	O	964	965	.	.	O	.	O	10	P	O

O	O	O	966	969	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	970	979	secretion	secretion	I-NP	NN	O	3	NMOD	O
O	O	O	980	986	levels	level	I-NP	NNS	O	20	SUB	O
O	O	O	987	989	of	of	B-PP	IN	O	3	NMOD	O
T2	B-Protein	B-Protein	990	1001	interleukin	interleukin	B-NP	NN	B-protein	16	NMOD	B-protein
T2	I-Protein	I-Protein	1001	1002	-	-	B-NP	HYPH	O	5	P	O
T2	I-Protein	I-Protein	1002	1003	6	6	I-NP	CD	O	5	NMOD	O
O	O	O	1004	1005	(	(	O	(	O	12	DEP	O
T3	B-Protein	B-Protein	1005	1007	IL	IL	B-NP	NN	B-protein	10	NMOD	B-protein
T3	I-Protein	I-Protein	1007	1008	-	-	B-NP	HYPH	I-protein	12	DEP	I-protein
T3	I-Protein	I-Protein	1008	1009	6	6	I-NP	CD	I-protein	10	NMOD	I-protein
O	O	O	1009	1010	)	)	O	)	O	5	NMOD	O
O	O	O	1011	1014	and	and	O	CC	O	16	NMOD	O
T4	B-Protein	B-Protein	1015	1018	von	von	B-NP	NN	B-protein	16	NMOD	B-protein
T4	I-Protein	I-Protein	1019	1029	Willebrand	Willebrand	I-NP	NN	I-protein	16	NMOD	I-protein
T4	I-Protein	I-Protein	1030	1036	factor	factor	I-NP	NN	I-protein	4	PMOD	I-protein
O	O	O	1037	1038	(	(	O	(	O	19	DEP	O
T5	B-Protein	B-Protein	1038	1041	vWF	vWF	B-NP	NN	B-protein	19	DEP	B-protein
O	O	O	1041	1042	)	)	O	)	O	16	NMOD	O
O	O	O	1043	1047	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1048	1058	determined	determine	I-VP	VBN	O	20	VC	O
O	O	O	1058	1059	,	,	O	,	O	21	P	O
O	O	O	1060	1062	to	to	B-VP	TO	O	24	VMOD	O
O	O	O	1063	1068	serve	serve	I-VP	VB	O	21	VMOD	O
O	O	O	1069	1071	as	as	B-PP	IN	O	24	VMOD	O
O	O	O	1072	1079	markers	marker	B-NP	NNS	O	25	PMOD	O
O	O	O	1080	1083	for	for	B-PP	IN	O	26	NMOD	O
O	O	O	1084	1086	EC	EC	B-NP	NN	B-cell_type	29	NMOD	B-cell_type
O	O	O	1087	1097	activation	activation	I-NP	NN	O	27	PMOD	O
O	O	O	1097	1098	.	.	O	.	O	20	P	O

O	O	O	1099	1102	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	1103	1112	activated	activate	I-NP	VBN	B-cell_line	3	NMOD	B-cell_line
O	O	O	1113	1115	EC	EC	I-NP	NN	I-cell_line	4	SUB	I-cell_line
O	O	O	1116	1120	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1121	1129	examined	examine	I-VP	VBN	O	4	VC	O
O	O	O	1130	1133	for	for	B-PP	IN	O	5	VMOD	O
O	O	O	1134	1137	the	the	B-NP	DT	O	8	NMOD	O
O	O	O	1138	1147	adherence	adherence	I-NP	NN	O	6	PMOD	O
O	O	O	1148	1150	of	of	B-PP	IN	O	8	NMOD	O
O	O	O	1151	1152	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	1153	1162	monocytic	monocytic	I-NP	JJ	B-cell_line	13	NMOD	B-cell_line
O	O	O	1163	1167	cell	cell	I-NP	NN	I-cell_line	13	NMOD	I-cell_line
O	O	O	1168	1172	line	line	I-NP	NN	I-cell_line	9	PMOD	I-cell_line
O	O	O	1173	1174	(	(	O	(	O	16	DEP	O
O	O	O	1174	1178	U937	U937	B-NP	NN	B-cell_line	16	DEP	B-cell_line
O	O	O	1178	1179	)	)	O	)	O	13	NMOD	O
O	O	O	1179	1180	,	,	O	,	O	6	P	O
O	O	O	1181	1183	as	as	B-CONJP	RB	O	6	PMOD	O
O	O	O	1184	1188	well	well	I-CONJP	RB	O	18	DEP	O
O	O	O	1189	1191	as	as	I-CONJP	IN	O	18	DEP	O
O	O	O	1192	1195	for	for	B-PP	IN	O	6	PMOD	O
O	O	O	1196	1206	expression	expression	B-NP	NN	O	21	PMOD	O
O	O	O	1207	1209	of	of	B-PP	IN	O	22	NMOD	O
T6	B-Protein	B-Protein	1210	1218	vascular	vascular	B-NP	JJ	B-protein	27	NMOD	B-protein
T6	I-Protein	I-Protein	1219	1223	cell	cell	I-NP	NN	I-protein	27	NMOD	I-protein
T6	I-Protein	I-Protein	1224	1232	adhesion	adhesion	I-NP	NN	I-protein	27	NMOD	I-protein
T6	I-Protein	I-Protein	1233	1241	molecule	molecule	I-NP	NN	I-protein	38	NMOD	I-protein
T6	I-Protein	I-Protein	1242	1243	1	1	I-NP	CD	I-protein	27	NMOD	I-protein
O	O	O	1243	1244	,	,	I-NP	,	O	38	P	O
T7	B-Protein	B-Protein	1245	1258	intercellular	intercellular	I-NP	JJ	B-protein	32	NMOD	B-protein
T7	I-Protein	I-Protein	1259	1267	adhesion	adhesion	I-NP	NN	I-protein	32	NMOD	I-protein
T7	I-Protein	I-Protein	1268	1276	molecule	molecule	I-NP	NN	I-protein	38	NMOD	I-protein
T7	I-Protein	I-Protein	1277	1278	1	1	I-NP	CD	I-protein	32	NMOD	I-protein
O	O	O	1278	1279	,	,	O	,	O	38	P	O
O	O	O	1280	1283	and	and	O	CC	O	38	NMOD	O
T8	B-Protein	B-Protein	1284	1285	E	E	B-NP	NN	B-protein	38	NMOD	B-protein
T8	I-Protein	I-Protein	1285	1286	-	-	B-NP	HYPH	I-protein	38	NMOD	I-protein
T8	I-Protein	I-Protein	1286	1294	selectin	selectin	I-NP	NN	I-protein	23	PMOD	I-protein
O	O	O	1294	1295	.	.	O	.	O	4	P	O

O	O	O	1296	1298	In	In	B-PP	IN	O	12	VMOD	O
O	O	O	1299	1307	addition	addition	B-NP	NN	O	1	PMOD	O
O	O	O	1307	1308	,	,	O	,	O	12	P	O
O	O	O	1309	1316	nuclear	nuclear	B-NP	JJ	O	5	NMOD	O
O	O	O	1317	1325	extracts	extract	I-NP	NNS	O	12	SUB	O
O	O	O	1326	1328	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	1329	1332	the	the	B-NP	DT	O	8	NMOD	O
O	O	O	1333	1338	mAECA	mAECA	I-NP	NNS	B-protein	11	NMOD	B-protein
O	O	O	1338	1339	-	-	B-VP	HYPH	O	11	NMOD	O
O	O	O	1339	1346	treated	treat	B-NP	VBN	O	11	NMOD	O
O	O	O	1347	1349	EC	EC	I-NP	NN	B-cell_type	6	PMOD	B-cell_type
O	O	O	1350	1354	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1355	1363	analyzed	analyze	I-VP	VBN	O	12	VC	O
O	O	O	1364	1367	for	for	B-PP	IN	O	13	VMOD	O
O	O	O	1368	1371	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	1372	1381	induction	induction	I-NP	NN	O	14	PMOD	O
O	O	O	1382	1384	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	1385	1398	translocation	translocation	B-NP	NN	O	17	PMOD	O
O	O	O	1399	1401	of	of	B-PP	IN	O	18	NMOD	O
T14	B-Entity	B-Entity	1402	1409	nuclear	nuclear	B-NP	JJ	B-protein	22	NMOD	B-protein
T14	I-Entity	I-Entity	1410	1416	factor	factor	I-NP	NN	I-protein	22	NMOD	I-protein
T14	I-Entity	I-Entity	1417	1423	kappaB	kappaB	I-NP	NN	I-protein	19	PMOD	I-protein
O	O	O	1424	1425	(	(	O	(	O	27	DEP	O
T15	B-Entity	B-Entity	1425	1427	NF	NF	B-NP	NN	B-protein	26	NMOD	B-protein
T15	I-Entity	I-Entity	1427	1428	-	-	B-NP	HYPH	I-protein	26	P	I-protein
T15	I-Entity	I-Entity	1428	1434	kappaB	kappaB	I-NP	NN	I-protein	27	DEP	I-protein
O	O	O	1434	1435	)	)	O	)	O	22	NMOD	O
O	O	O	1435	1436	,	,	O	,	O	13	P	O
O	O	O	1437	1442	using	use	B-VP	VBG	O	13	VMOD	O
O	O	O	1443	1444	a	a	B-NP	DT	O	35	NMOD	O
O	O	O	1445	1453	specific	specific	I-NP	JJ	O	35	NMOD	O
T16,T17	B-Entity,B-Entity	B-Entity,B-Entity	1454	1456	NF	NF	I-NP	NN	B-protein	35	NMOD	B-protein
T16,T17	I-Entity,I-Entity	I-Entity,I-Entity	1456	1457	-	-	I-NP	HYPH	I-protein	35	NMOD	I-protein
T16,T17	I-Entity,I-Entity	I-Entity,I-Entity	1457	1463	kappaB	kappaB	I-NP	NN	I-protein	35	NMOD	I-protein
T16	I-Entity	I-Entity	1464	1474	oligoprobe	oligoprobe	I-NP	NN	O	29	OBJ	O
O	O	O	1475	1477	in	in	B-PP	IN	O	35	NMOD	O
O	O	O	1478	1480	an	an	B-NP	DT	O	41	NMOD	O
O	O	O	1481	1496	electrophoretic	electrophoretic	I-NP	JJ	O	41	NMOD	O
O	O	O	1497	1505	mobility	mobility	I-NP	NN	O	41	NMOD	O
O	O	O	1506	1511	shift	shift	I-NP	NN	O	41	NMOD	O
O	O	O	1512	1517	assay	assay	I-NP	NN	O	36	PMOD	O
O	O	O	1517	1518	.	.	O	.	O	12	P	O

O	O	O	1519	1526	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	O
O	O	O	1526	1527	:	:	O	:	O	1	P	O
O	O	O	1528	1531	Six	Six	B-NP	CD	O	4	NMOD	O
O	O	O	1532	1537	mAECA	mAECA	I-NP	NNS	B-protein	5	SUB	B-protein
O	O	O	1538	1542	were	be	B-VP	VBD	O	1	NMOD	O
O	O	O	1543	1551	selected	select	I-VP	VBN	O	5	VC	O
O	O	O	1551	1552	,	,	O	,	O	6	P	O
O	O	O	1553	1556	the	the	B-NP	DT	O	9	NMOD	O
O	O	O	1557	1564	mixture	mixture	I-NP	NN	O	10	NMOD	O
O	O	O	1565	1567	of	of	B-PP	IN	O	6	VMOD	O
O	O	O	1568	1573	which	which	B-NP	WDT	O	10	PMOD	O
O	O	O	1574	1582	produced	produce	B-VP	VBD	O	10	SBAR	O
O	O	O	1583	1586	100	100	B-NP	CD	O	14	AMOD	O
O	O	O	1586	1587	%	%	I-NP	NN	O	15	NMOD	O
O	O	O	1588	1598	inhibition	inhibition	I-NP	NN	O	12	OBJ	O
O	O	O	1599	1601	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	1602	1609	binding	binding	B-NP	NN	O	16	PMOD	O
O	O	O	1610	1612	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	1613	1616	the	the	B-NP	DT	O	21	NMOD	O
O	O	O	1617	1625	original	original	I-NP	JJ	O	21	NMOD	O
O	O	O	1626	1629	IgG	IgG	I-NP	NN	B-protein	18	PMOD	B-protein
O	O	O	1630	1631	(	(	O	(	O	29	DEP	O
O	O	O	1631	1635	from	from	B-PP	IN	O	29	DEP	O
O	O	O	1636	1639	the	the	B-NP	DT	O	25	NMOD	O
O	O	O	1640	1647	patient	patient	I-NP	NN	O	23	PMOD	O
O	O	O	1648	1652	with	with	B-PP	IN	O	25	NMOD	O
O	O	O	1653	1661	Takayasu	Takayasu	B-NP	NN	O	28	NMOD	O
O	O	O	1662	1671	arteritis	arteritis	I-NP	NN	O	26	PMOD	O
O	O	O	1671	1672	)	)	O	)	O	21	NMOD	O
O	O	O	1673	1675	to	to	B-PP	TO	O	17	NMOD	O
O	O	O	1676	1681	HUVEC	HUVEC	B-NP	NN	B-cell_line	30	PMOD	B-cell_line
O	O	O	1681	1682	.	.	O	.	O	1	P	O

O	O	O	1683	1686	All	All	B-NP	DT	O	2	NMOD	O
O	O	O	1687	1692	mAECA	mAECA	I-NP	NNS	B-protein	3	SUB	B-protein
O	O	O	1693	1702	possessed	possess	B-VP	VBD	O	12	VMOD	O
O	O	O	1703	1707	high	high	B-NP	JJ	O	5	NMOD	O
O	O	O	1708	1716	activity	activity	I-NP	NN	O	3	OBJ	O
O	O	O	1717	1724	against	against	B-PP	IN	O	3	VMOD	O
O	O	O	1725	1738	macrovascular	macrovascular	B-NP	JJ	B-cell_line	8	NMOD	B-cell_line
O	O	O	1739	1741	EC	EC	I-NP	NN	I-cell_line	6	PMOD	I-cell_line
O	O	O	1741	1742	,	,	O	,	O	12	P	O
O	O	O	1743	1746	but	but	O	CC	O	12	VMOD	O
O	O	O	1747	1751	none	none	B-NP	NN	O	12	SUB	O
O	O	O	1752	1755	had	have	B-VP	VBD	O	0	ROOT	O
O	O	O	1756	1767	significant	significant	B-NP	JJ	O	16	NMOD	O
O	O	O	1768	1785	antimicrovascular	antimicrovascular	I-NP	JJ	O	16	NMOD	O
O	O	O	1786	1788	EC	EC	I-NP	NN	O	16	NMOD	O
O	O	O	1789	1797	activity	activity	I-NP	NN	O	12	OBJ	O
O	O	O	1797	1798	.	.	O	.	O	12	P	O

O	O	O	1799	1802	The	The	B-NP	DT	O	8	NMOD	O
O	O	O	1803	1808	mAECA	mAECA	I-NP	NNS	B-protein	8	NMOD	B-protein
O	O	O	1808	1809	,	,	O	,	O	8	P	O
O	O	O	1810	1813	but	but	O	CC	O	8	NMOD	O
O	O	O	1814	1817	not	not	O	RB	O	4	DEP	O
O	O	O	1818	1824	normal	normal	B-NP	JJ	B-protein	8	NMOD	B-protein
O	O	O	1825	1830	human	human	I-NP	JJ	I-protein	8	NMOD	I-protein
T9	B-Protein	B-Protein	1831	1834	IgG	IgG	I-NP	NN	I-protein	10	SUB	I-protein
O	O	O	1834	1835	,	,	O	,	O	8	P	O
O	O	O	1836	1839	had	have	B-VP	VBD	O	0	ROOT	O
O	O	O	1840	1844	anti	anti	B-PRT	AFX	O	16	NMOD	O
O	O	O	1844	1845	-	-	B-NP	HYPH	O	16	NMOD	O
O	O	O	1845	1850	human	human	I-NP	JJ	B-cell_type	16	NMOD	B-cell_type
O	O	O	1851	1857	aortic	aortic	I-NP	JJ	I-cell_type	16	NMOD	I-cell_type
O	O	O	1858	1860	EC	EC	I-NP	NN	I-cell_type	16	NMOD	I-cell_type
O	O	O	1861	1869	activity	activity	I-NP	NN	O	10	OBJ	O
O	O	O	1869	1870	.	.	O	.	O	10	P	O

O	O	O	1871	1875	Four	Four	B-NP	CD	O	9	SUB	O
O	O	O	1876	1878	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	1879	1882	the	the	B-NP	DT	O	7	NMOD	O
O	O	O	1883	1884	6	6	I-NP	CD	O	7	NMOD	O
O	O	O	1885	1890	mAECA	mAECA	I-NP	NNS	B-protein	7	NMOD	B-protein
O	O	O	1891	1900	activated	activate	B-VP	VBD	O	7	NMOD	O
O	O	O	1901	1903	EC	EC	B-NP	NN	B-cell_type	2	PMOD	B-cell_type
O	O	O	1903	1904	,	,	O	,	O	1	P	O
O	O	O	1905	1915	manifested	manifest	B-VP	VBN	O	0	ROOT	O
O	O	O	1916	1918	by	by	B-PP	IN	O	9	VMOD	O
O	O	O	1919	1928	increased	increase	B-NP	VBN	O	17	NMOD	O
T10	B-Protein	B-Protein	1929	1931	IL	IL	I-NP	NN	B-protein	17	NMOD	B-protein
T10	I-Protein	I-Protein	1931	1932	-	-	I-NP	HYPH	I-protein	12	NMOD	I-protein
T10	I-Protein	I-Protein	1932	1933	6	6	I-NP	CD	I-protein	13	NMOD	I-protein
O	O	O	1934	1937	and	and	I-NP	CC	O	17	NMOD	O
T11	B-Protein	B-Protein	1938	1941	vWF	vWF	I-NP	NN	B-protein	17	NMOD	B-protein
O	O	O	1942	1951	secretion	secretion	I-NP	NN	O	10	PMOD	O
O	O	O	1951	1952	.	.	O	.	O	9	P	O

O	O	O	1953	1956	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	1957	1958	4	4	I-NP	CD	O	3	NMOD	O
O	O	O	1959	1964	mAECA	mAECA	I-NP	NNS	B-protein	4	SUB	B-protein
O	O	O	1965	1972	induced	induce	B-VP	VBD	O	0	ROOT	O
O	O	O	1973	1975	EC	EC	B-NP	NN	B-cell_type	6	NMOD	B-cell_type
O	O	O	1976	1986	expression	expression	I-NP	NN	O	4	OBJ	O
O	O	O	1987	1989	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	1990	1998	adhesion	adhesion	B-NP	NN	B-protein	9	NMOD	B-protein
O	O	O	1999	2008	molecules	molecule	I-NP	NNS	I-protein	7	PMOD	I-protein
O	O	O	2009	2012	and	and	O	CC	O	4	VMOD	O
O	O	O	2013	2022	increased	increase	B-NP	VBN	O	12	NMOD	O
O	O	O	2023	2031	adhesion	adhesion	I-NP	NN	O	4	VMOD	O
O	O	O	2032	2034	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	2035	2039	U937	U937	B-NP	NN	B-cell_line	16	NMOD	B-cell_line
O	O	O	2040	2049	monocytic	monocytic	I-NP	JJ	I-cell_line	16	NMOD	I-cell_line
O	O	O	2050	2055	cells	cell	I-NP	NNS	I-cell_line	13	PMOD	I-cell_line
O	O	O	2056	2058	to	to	B-PP	TO	O	12	NMOD	O
O	O	O	2059	2061	EC	EC	B-NP	NN	B-cell_type	17	PMOD	B-cell_type
O	O	O	2061	2062	.	.	O	.	O	4	P	O

O	O	O	2063	2065	In	In	B-PP	IN	O	6	VMOD	O
O	O	O	2066	2074	addition	addition	B-NP	NN	O	1	PMOD	O
O	O	O	2074	2075	,	,	O	,	O	6	P	O
O	O	O	2076	2081	these	these	B-NP	DT	O	5	NMOD	O
O	O	O	2082	2087	mAECA	mAECA	I-NP	NNS	B-protein	6	SUB	B-protein
O	O	O	2088	2098	stimulated	stimulate	B-VP	VBD	O	0	ROOT	O
O	O	O	2099	2102	the	the	B-NP	DT	O	9	NMOD	O
O	O	O	2103	2110	nuclear	nuclear	I-NP	JJ	O	9	NMOD	O
O	O	O	2111	2124	translocation	translocation	I-NP	NN	O	6	OBJ	O
O	O	O	2125	2127	of	of	B-PP	IN	O	9	NMOD	O
O	O	O	2128	2131	the	the	B-NP	DT	O	16	NMOD	O
T18	B-Entity	B-Entity	2132	2134	NF	NF	I-NP	NN	B-protein	16	NMOD	B-protein
T18	I-Entity	I-Entity	2134	2135	-	-	B-NP	HYPH	I-protein	16	NMOD	I-protein
T18	I-Entity	I-Entity	2135	2141	kappaB	kappaB	I-NP	NN	I-protein	16	NMOD	I-protein
T18	I-Entity	I-Entity	2142	2155	transcription	transcription	I-NP	NN	I-protein	16	NMOD	I-protein
T18	I-Entity	I-Entity	2156	2162	factor	factor	I-NP	NN	I-protein	10	PMOD	I-protein
O	O	O	2162	2163	.	.	O	.	O	6	P	O

O	O	O	2164	2174	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT	O
O	O	O	2174	2175	:	:	O	:	O	1	P	O
O	O	O	2176	2179	Our	Our	B-NP	PRP$	O	4	NMOD	O
O	O	O	2180	2188	findings	finding	I-NP	NNS	O	5	SUB	O
O	O	O	2189	2196	suggest	suggest	B-VP	VBP	O	1	NMOD	O
O	O	O	2197	2201	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	O	2202	2206	AECA	AECA	B-NP	NNS	B-protein	8	SUB	B-protein
O	O	O	2207	2210	may	may	B-VP	MD	O	6	SBAR	O
O	O	O	2211	2219	directly	directly	I-VP	RB	O	8	VMOD	O
O	O	O	2220	2229	stimulate	stimulate	I-VP	VB	O	8	VC	O
O	O	O	2230	2232	EC	EC	B-NP	NN	B-cell_type	10	OBJ	B-cell_type
O	O	O	2233	2235	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	2236	2244	Takayasu	Takayasu	B-NP	NN	O	14	NMOD	O
O	O	O	2245	2254	arteritis	arteritis	I-NP	NN	O	12	PMOD	O
O	O	O	2255	2262	through	through	B-PP	IN	O	10	VMOD	O
O	O	O	2263	2272	elevation	elevation	B-NP	NN	O	15	PMOD	O
O	O	O	2273	2275	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	2276	2284	adhesion	adhesion	B-NP	NN	B-protein	20	NMOD	B-protein
O	O	O	2285	2293	molecule	molecule	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	O	2294	2304	expression	expression	I-NP	NN	O	17	PMOD	O
O	O	O	2305	2315	associated	associate	B-VP	VBN	O	20	NMOD	O
O	O	O	2316	2320	with	with	B-PP	IN	O	21	VMOD	O
T19	B-Entity	B-Entity	2321	2323	NF	NF	B-NP	NN	B-protein	25	NMOD	B-protein
T19	I-Entity	I-Entity	2323	2324	-	-	B-NP	HYPH	I-protein	25	NMOD	I-protein
T19	I-Entity	I-Entity	2324	2330	kappaB	kappaB	I-NP	NN	I-protein	26	NMOD	I-protein
O	O	O	2331	2341	activation	activation	I-NP	NN	O	28	NMOD	O
O	O	O	2342	2345	and	and	O	CC	O	28	NMOD	O
O	O	O	2346	2354	adhesion	adhesion	B-NP	NN	O	22	PMOD	O
O	O	O	2355	2357	of	of	B-PP	IN	O	28	NMOD	O
O	O	O	2358	2367	monocytes	monocyte	B-NP	NNS	B-cell_type	29	PMOD	B-cell_type
O	O	O	2367	2368	,	,	O	,	O	5	P	O
O	O	O	2369	2372	and	and	O	CC	O	5	VMOD	O
O	O	O	2373	2376	may	may	B-VP	MD	O	5	VMOD	O
O	O	O	2377	2386	therefore	therefore	I-VP	RB	O	33	VMOD	O
O	O	O	2387	2391	play	play	I-VP	VB	O	33	VC	O
O	O	O	2392	2393	a	a	B-NP	DT	O	38	NMOD	O
O	O	O	2394	2404	pathogenic	pathogenic	I-NP	JJ	O	38	NMOD	O
O	O	O	2405	2409	role	role	I-NP	NN	O	35	OBJ	O
O	O	O	2410	2412	in	in	B-PP	IN	O	35	VMOD	O
O	O	O	2413	2416	the	the	B-NP	DT	O	41	NMOD	O
O	O	O	2417	2428	development	development	I-NP	NN	O	39	PMOD	O
O	O	O	2429	2431	of	of	B-PP	IN	O	41	NMOD	O
O	O	O	2432	2435	the	the	B-NP	DT	O	44	NMOD	O
O	O	O	2436	2448	vasculopathy	vasculopathy	I-NP	NN	O	42	PMOD	O
O	O	O	2449	2451	in	in	B-PP	IN	O	44	NMOD	O
O	O	O	2452	2460	Takayasu	Takayasu	B-NP	NN	O	47	NMOD	O
O	O	O	2461	2470	arteritis	arteritis	I-NP	NN	O	45	PMOD	O
O	O	O	2470	2471	.	.	O	.	O	1	P	O
